Clinical Trial – Immune Response to Shingles Vaccination – Shingles

Answer 1

The purpose of this study is to learn more about the immune response to varicella zoster virus (VZV). Participants 70 years of age or older will receive the FDA-approved shingles vaccine (Zostavax). Blood samples and optional skin biopsies will be obtained before and after vaccination to study the immune responses to shingles vaccination.

Study Type :	Interventional  (Clinical Trial)
Estimated Enrollment :	50 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Basic Science
Official Title:	Immune Response to Shingles Vaccination
Study Start Date :	February 2016
Estimated Primary Completion Date :	December 2018
Estimated Study Completion Date :	December 2018

Contacts
Contact: Study Coordinator Virology Research Clinic	206-520-4340	vrc@uw.edu

 

ClinicalTrials.gov Identifier:

NCT02624375

For enrollment please visit www.clinicaltrials.gov.

Answer 2

body aches, inflammation at injection site and general weakness

Comments

How long after vaccination? Do you have a fever? Generally weakness and local inflammation are common within a few days after vaccine shots and can generally disappear days later. If you feel very uncomfortable, calling your doctor is recommended.